These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 31877168)
1. Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug. Perlstein D; Shlagman O; Kogan Y; Halevi-Tobias K; Yakobson A; Lazarev I; Agur Z PLoS One; 2019; 14(12):e0226869. PubMed ID: 31877168 [TBL] [Abstract][Full Text] [Related]
2. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. Tsur N; Kogan Y; Avizov-Khodak E; Vaeth D; Vogler N; Utikal J; Lotem M; Agur Z J Transl Med; 2019 Oct; 17(1):338. PubMed ID: 31590677 [TBL] [Abstract][Full Text] [Related]
3. Blood Assay Predicts Response to Pembrolizumab. Cancer Discov; 2016 Nov; 6(11):1200. PubMed ID: 27698203 [TBL] [Abstract][Full Text] [Related]
4. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Nishino M; Giobbie-Hurder A; Manos MP; Bailey N; Buchbinder EI; Ott PA; Ramaiya NH; Hodi FS Clin Cancer Res; 2017 Aug; 23(16):4671-4679. PubMed ID: 28592629 [No Abstract] [Full Text] [Related]
5. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895 [TBL] [Abstract][Full Text] [Related]
7. Response of patients with melanoma to immune checkpoint blockade - insights gleaned from analysis of a new mathematical mechanistic model. Tsur N; Kogan Y; Rehm M; Agur Z J Theor Biol; 2020 Jan; 485():110033. PubMed ID: 31580835 [TBL] [Abstract][Full Text] [Related]
8. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma. Roncati L Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488 [TBL] [Abstract][Full Text] [Related]
9. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. Takeuchi Y; Tanemura A; Tada Y; Katayama I; Kumanogoh A; Nishikawa H Int Immunol; 2018 Feb; 30(1):13-22. PubMed ID: 29294043 [TBL] [Abstract][Full Text] [Related]
10. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916 [TBL] [Abstract][Full Text] [Related]
12. Cancer immunology and melanoma immunotherapy. Linck RDM; Costa RLP; Garicochea B An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441 [TBL] [Abstract][Full Text] [Related]
13. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Longoria TC; Tewari KS Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741 [TBL] [Abstract][Full Text] [Related]
16. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174 [No Abstract] [Full Text] [Related]
17. [Pembrolizumab for the treatment of melanoma: updates and perspectives.]. Chiarion Sileni V; Mandalà M; Queirolo P Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903 [TBL] [Abstract][Full Text] [Related]
18. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Ribas A; Medina T; Kummar S; Amin A; Kalbasi A; Drabick JJ; Barve M; Daniels GA; Wong DJ; Schmidt EV; Candia AF; Coffman RL; Leung ACF; Janssen RS Cancer Discov; 2018 Oct; 8(10):1250-1257. PubMed ID: 30154193 [TBL] [Abstract][Full Text] [Related]